These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34595943

  • 1. The effectiveness and value of belimumab and voclosporin for lupus nephritis.
    Tice JA, Mandrik O, Thokala P, Fotheringham J, Pearson SD.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1495-1499. PubMed ID: 34595943
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis.
    Tice JA, Touchette DR, Lien PW, Agboola F, Nikitin D, Pearson SD.
    J Manag Care Spec Pharm; 2022 Jan; 28(1):119-124. PubMed ID: 34949112
    [Abstract] [Full Text] [Related]

  • 3. The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors.
    Agboola F, Rind DM, Walton SM, Herron-Smith S, Quach D, Pearson SD.
    J Manag Care Spec Pharm; 2021 May; 27(5):667-673. PubMed ID: 33908280
    [Abstract] [Full Text] [Related]

  • 4. The effectiveness and value of aducanumab for Alzheimer's disease.
    Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1613-1617. PubMed ID: 34714106
    [Abstract] [Full Text] [Related]

  • 5. The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder.
    Tice JA, Whittington MD, Campbell JD, Pearson SD.
    J Manag Care Spec Pharm; 2021 Apr; 27(4):528-532. PubMed ID: 33769860
    [Abstract] [Full Text] [Related]

  • 6. The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
    Beinfeld M, Atlas SJ, Touchette D, McKenna A, Rind D, Pearson SD.
    J Manag Care Spec Pharm; 2021 Jun; 27(6):797-804. PubMed ID: 34057394
    [Abstract] [Full Text] [Related]

  • 7. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM, Pandey R, Fazioli K, Ollendorf DA, Carlson JJ.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [Abstract] [Full Text] [Related]

  • 8. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.
    Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2022 Jan; 28(1):108-114. PubMed ID: 34949111
    [Abstract] [Full Text] [Related]

  • 9. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value.
    Beinfeld M, Wasfy JH, Walton S, Sarker J, Nhan E, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2022 Mar; 28(3):369-375. PubMed ID: 35199575
    [Abstract] [Full Text] [Related]

  • 10. The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD.
    Agboola F, Lin GA, Kazi DS, McKenna A, Pearson SD.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):961-966. PubMed ID: 34185561
    [Abstract] [Full Text] [Related]

  • 11. The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis.
    Pandey R, Ollendorf DA, Fazioli K, Bloudek L, Carlson JJ, Pearson SD.
    J Manag Care Spec Pharm; 2021 Mar; 27(3):405-410. PubMed ID: 33645245
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
    Nikitin D, Makam AN, Suh K, McKenna A, Carlson JJ, Richardson M, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2023 Feb; 29(2):216-221. PubMed ID: 36705279
    [Abstract] [Full Text] [Related]

  • 13. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma.
    Beinfeld M, Lee S, McQueen B, Fluetsch N, Pearson SD, Ollendorf DA.
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1315-1320. PubMed ID: 34464215
    [Abstract] [Full Text] [Related]

  • 14. The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.
    Fazioli KT, Rind DM, Guzauskas GF, Hansen RN, Pearson SD.
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1072-1076. PubMed ID: 32857658
    [Abstract] [Full Text] [Related]

  • 15. The effectiveness and value of novel treatments for cystic fibrosis.
    Tice JA, Kuntz KM, Wherry K, Seidner M, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
    [Abstract] [Full Text] [Related]

  • 16. The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy.
    Agboola F, Lin GA, Fluetsch N, Walton SM, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2020 Apr; 26(4):361-366. PubMed ID: 32223597
    [Abstract] [Full Text] [Related]

  • 17. Oral treatments for outpatient COVID-19: Effectiveness and value.
    Beinfeld M, Yeung K, Whittington MD, Mohammed R, Nhan E, Pearson SD.
    J Manag Care Spec Pharm; 2022 Aug; 28(8):903-909. PubMed ID: 35876296
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN.
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.